Case number 1:17-cv-00227
Novo Nordisk Inc. et al v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 20, 2019 | 102 | Redacted Document (3) Docket Text: REDACTED VERSION of [97] Exhibit to a Document by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Mar 20, 2019 | 103 | Redacted Document (3) Docket Text: REDACTED VERSION of [99] Exhibit to a Document by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Mar 18, 2019 | N/A | Redaction Notice (0) Docket Text: REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [91]. (lih) |
| Mar 18, 2019 | N/A | Settlement Conference (0) Docket Text: Minute Entry for proceedings held before Judge Joseph F. Bataillon - Hearing held on 3/18/2019. The parties have settled. Bench trial cancelled. Stipulated consent judgment and injunction to be issued. Hearing held in Omaha, NE. Appearance for Plaintiff: Jeffrey J. Oelke, Ryan P. Johnson, Thomas Culhane; Appearance for Defendant: Thomas F. Fleming, Jeanna Wacker, Patrick Cooper; Courtoom Deputy: Amy Brunswick. (Court Reporter Lisa Grimminger.) (Brunswick, Amy) |
| Mar 18, 2019 | 100 | Redacted Document (6) Docket Text: REDACTED VERSION of [91] Exhibit to a Document by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) Modified on 3/18/2019 (lih). |
| Mar 18, 2019 | 101 | Consent Judgment (3) Docket Text: STIPULATED CONSENT JUDGMENT AND INJUNCTION. Signed by Judge Joseph F. Bataillon on 3/18/2019. (ceg) |
| Mar 18, 2019 | 104 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,268,343 81; 8,114,833 82; 8,846,618 82; 9,265,893 82; RE41,956 E. (Attachments: # (1) Consent Judgment)(ceg) |
| Mar 18, 2019 | 104 | Consent Judgment (3) |
| Mar 15, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [98] MOTION for Pro Hac Vice Appearance of Attorney Patrick S. Cooper and Robert W. Futhey. Signed by Judge Sherry R. Fallon on 3/15/2019. (lih) |
| Mar 13, 2019 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The motion for pro hac previously filed as D.I. 98 has been deleted per the request of counsel. (lih) |
| Mar 13, 2019 | 98 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Patrick S. Cooper and Robert W. Futhey - filed by Teva Pharmaceuticals USA, Inc.. Motions referred to Sherry R. Fallon.(Keller, Karen) |
| Mar 12, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [95] Joint STIPULATION to Narrow the Number of Asserted Claims and to Not Contest the Infringement of Certain Claims, [96] MOTION for Pro Hac Vice Appearance of Attorney Thomas J. Culhane. Signed by Judge Sherry R. Fallon on 3/12/2019. (lih) |
| Mar 12, 2019 | N/A | Oral Order (0) Docket Text: ORAL ORDER re [94] Letter to Honorable Joseph F. Bataillon. Local Delaware counsel is not required to attend the bench trial scheduled to begin on March 18, 2019 in Omaha, NE. Delaware counsel will remain available remotely. Signed by Judge Joseph F. Bataillon on 03/12/19. (AEV) |
| Mar 12, 2019 | 96 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Thomas J. Culhane - filed by Novo Nordisk A/S, Novo Nordisk Inc.. Motions referred to Sherry R. Fallon.(Egan, Brian) |
| Mar 11, 2019 | 95 | Stipulation (2) Docket Text: Joint STIPULATION to Narrow the Number of Asserted Claims and to Not Contest the Infringement of Certain Claims by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Mar 8, 2019 | 93 | Letter (2) Docket Text: Letter to the Honorable Sherry R. Fallon from Brian P. Egan regarding Update on Status of the Discovery Disputes. (Egan, Brian) |
| Mar 8, 2019 | 94 | Letter (1) Docket Text: Letter to the Honorable Joseph F. Bataillon from Brian P. Egan regarding Excuse Delaware Counsel from Attending Trial. (Attachments: # (1) Exhibit)(Egan, Brian) |
| Mar 8, 2019 | 94 | Exhibit (2) |
| Mar 7, 2019 | 92 | Redacted Document (30) Docket Text: REDACTED VERSION of [90] Amended Document by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Mar 6, 2019 | N/A | Pretrial Conference - Final (0) Docket Text: Minute Entry for proceedings held before Judge Sherry R. Fallon - Final Pretrial Teleconference held on 3/6/2019. (Court Reporter T. Carroll (Hawkins Reporting).) (lih) |
| Mar 6, 2019 | N/A | Oral Order (0) Docket Text: Oral Order: IT IS HEREBY ORDERED, for the reasons stated at the Pretrial Conference on March 6, 2019, that the Joint Proposed Pretrial Order (Pretrial Order) (D.I. 78 & 79) is ADOPTED and the parties shall proceed as follows: (1) On or before March 7, 2019, Plaintiff shall file an amended Exhibit 6 to the Pretrial Order; (2) On or before March 8, 2019, the parties shall each provide confirmation regarding the resolution of the discovery disputes identified at Exhibits 14 and 15 of the Pretrial Order; and (3) On or before March 11, 2019, the parties shall file a stipulation narrowing the number of asserted claims and stipulating to the infringement of certain claims or, alternatively, shall submit a joint letter to the court indicating that agreement has not been reached. Ordered by Judge Sherry R. Fallon on 3/6/2019. (lih) |
| Feb 25, 2019 | 86 | Redacted Document (30) Docket Text: REDACTED VERSION of [85] Exhibit to a Document by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) Modified on 2/26/2019 (lih). |
| Feb 25, 2019 | 87 | Redacted Document (30) Docket Text: REDACTED VERSION of [82] Exhibit to a Document by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Feb 25, 2019 | 88 | Redacted Document (30) Docket Text: REDACTED VERSION of [78] Proposed Pretrial Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) Modified on 2/26/2019 (lih). |
| Feb 25, 2019 | 89 | Redacted Document (30) Docket Text: REDACTED VERSION of [79] Proposed Pretrial Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) Modified on 2/26/2019 (lih). |
| Feb 21, 2019 | N/A | Oral Order (0) Docket Text: ORAL ORDER- IT IS HEREBY ORDERED that: the pretrial and discovery dispute teleconference previously set in this matter for 2/20/2019 is RESCHEDULED to 3/6/2019 at 02:00 PM. Counsel for the plaintiff shall initiate the call to 302-573-4557. Ordered by Judge Sherry R. Fallon on 2/21/2019. (lih) |
| Feb 21, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [84] MOTION for Pro Hac Vice Appearance of Attorney Christopher T. Jagoe and Jeanna Wacker. Signed by Judge Sherry R. Fallon on 2/21/2019. (lih) |
| Feb 19, 2019 | N/A | Oral Order (0) Docket Text: ORAL ORDER- Pursuant to the joint email request of counsel, IT IS HEREBY ORDERED that: the pretrial conference and discovery dispute hearing set in this matter for 2/20/2019 is converted into a teleconference. Counsel for the plaintiff shall initiate the call to 302-573-4557. Ordered by Judge Sherry R. Fallon on 2/19/2019. (lih) |
| Feb 19, 2019 | 84 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Christopher T. Jagoe and Jeanna Wacker - filed by Teva Pharmaceuticals USA, Inc.. Motions referred to Sherry R. Fallon.(Keller, Karen) |
| Feb 15, 2019 | N/A | Oral Order (0) Docket Text: ORAL ORDER- The parties shall be prepared to present their arguments on the discovery disputes identified at D.I. [79], Exhibits 14-15, during the pretrial conference on February 20, 2019. Ordered by Judge Sherry R. Fallon on 2/15/2019. (lih) |
| Feb 15, 2019 | 83 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant's Supplemental Notice Pursuant to 35 U.S.C. § 282 filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Feb 14, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [81] STIPULATION TO EXTEND TIME to file redactions to the parties' Proposed Pretrial Order (D.I. 78-79) to February 25, 2019. Signed by Judge Sherry R. Fallon on 2/14/2019. (lih) |
| Feb 13, 2019 | 81 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to file redactions to the parties' Proposed Pretrial Order (D.I. 78-79) to February 25, 2019 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) |
| Feb 11, 2019 | 80 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant's Notice Pursuant to 35 U.S.C. § 282 filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Nov 19, 2018 | 77 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant's Third Amended Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Nov 5, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [76] STIPULATION to Further Amend the Scheduling Order. (PLEASE REFER TO ORDER FOR FURTHER DETAILS.) Signed by Judge Sherry R. Fallon on 11/5/2018. (lih) |
| Nov 2, 2018 | 76 | Stipulation (3) Docket Text: STIPULATION to Further Amend the Scheduling Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) |
| Oct 23, 2018 | 75 | Order (2) Docket Text: ORDER AMENDING TRIAL AND PRETRIAL DATES- Proposed Pretrial Order due by 2/6/2019. A Pretrial Conference is set for 2/20/2019 at 10:00 AM in Courtroom 6C before Judge Sherry R. Fallon. A 5-day Bench Trial is set for 3/18/2019 at 09:00 AM in Courtroom #3 before Judge Joseph F. Bataillon. Signed by Judge Sherry R. Fallon on 10/23/2018. (lih) |
| Oct 15, 2018 | 74 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of the Notice of Intended Trial Witnesses filed by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| Oct 10, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [73] MOTION for Pro Hac Vice Appearance of Attorney Catherine McCord. Signed by Judge Sherry R. Fallon on 10/10/2018. (lih) |
| Oct 10, 2018 | 73 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Catherine McCord of FENWICK & WEST LLP - filed by Novo Nordisk A/S, Novo Nordisk Inc.. Motions referred to Sherry R. Fallon.(Blumenfeld, Jack) |
| Oct 5, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [72] MOTION for Pro Hac Vice Appearance of Attorney Micah Rappazzo. Signed by Judge Sherry R. Fallon on 10/5/2018. (lih) |
| Oct 5, 2018 | 72 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Micah Rappazzo - filed by Teva Pharmaceuticals USA, Inc.. Motions referred to Sherry R. Fallon.(Keller, Karen) |
| Sep 10, 2018 | 70 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1. Rebuttal Expert Report of Christopher J. Soares, Ph.D.; 2. Report of Karl R. Leinsing, MSME, PE Regarding Non-Infringement of U.S. Patent Nos. 9,265,893 and RE41,956; and 3. Rebuttal Expert Report of James Lenhard, M.D. filed by Teva Pharmaceuticals USA, Inc..(Shaw, John) |
| Sep 10, 2018 | 71 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Rebuttal Expert Report of Charles E. Clemens Regarding Validity of U.S. Patent Nos. 9,265,893 and RE 41,956; (2) Rebuttal Expert Report of Peter M. Tessier, Ph.D. Regarding Validity of U.S. Patent Nos. 8,114,833 and 8,846,618; (3) Rebuttal Expert Report of Soumitra S. Ghosh, Ph.D.; and (4) Rebuttal Expert Report of Thomas W. Muir, Ph.D. Regarding Validity of U.S. Patent No. 6,268,343 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| Aug 10, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER Setting Teleconference: The Telephone Conference set for 8/17/2018 at 01:30 PM Eastern Time before Judge Mary Pat Thynge to discuss ADR has been rescheduled to 8/23/2018 at 03:00 PM Eastern Time. Plaintiffs' Counsel to initiate the call. Ordered by Judge Mary Pat Thynge on 8/10/2018. (fms) |
| Aug 8, 2018 | 68 | Order Adopting Report and Recommendations (2) Docket Text: ORDER ADOPTING REPORT AND RECOMMENDATIONS re [61] Report and Recommendations. Signed by Judge Joseph F. Bataillon on 8/8/2018. (crb) |
| Aug 6, 2018 | 67 | Notice (Other) (3) Docket Text: NOTICE of Change of Firm Affiliation and Withdrawal of Appearance by Novo Nordisk A/S, Novo Nordisk Inc. (Blumenfeld, Jack) |
| Jul 30, 2018 | 65 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Expert Report of Charles E. Clemens Regarding Infringement of U.S. Patent Nos. 9,265,893 and RE 41,956; (2) Opening Expert Report of Peter M. Tessier, Ph.D. Regarding Secondary Considerations; (3) Opening Expert Report of Peter M. Tessier, Ph.D. Regarding Patent Infringement by Teva Pharmaceuticals USA, Inc.; (4) Opening Expert Report of Steve P. Marso, M.D.; (5) Opening Expert Report of Robert E. Ratner, M.D. Regarding Secondary Considerations; (6) Opening Expert Report of Leonard J. Chyall, Ph.D. Regarding Infringement of Claims 1, 2, 3, and 14 of U.S. Patent No. 6,268,343 by Teva Pharmaceuticals USA, Inc.; (7) Opening Expert Report of Plaintiffs' Expert Thomas W. Muir, Ph.D.; (8) Opening Expert Report of Robert E. Ratner, M.D. Regarding Infringement of Claim 39 of U.S. Patent No. 6,268,343 by Teva Pharmaceuticals USA, Inc.; and (9) Expert Report of Christopher A. Vellturo, Ph.D. filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jul 30, 2018 | 66 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1. Opening Expert Report of Christopher J. Soares, Ph.D.; 2. Opening Expert Report of Karl R. Leinsing, MSME, PE Regarding Invalidity of U.S. Patent Nos. 9,265,893 and RE41,956; and 3. Opening Expert Report of Michael Hecht, Ph.D. filed by Teva Pharmaceuticals USA, Inc..(Shaw, John) |
| Jul 25, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [63] MOTION for Pro Hac Vice Appearance of Attorney Vigen Salmastlian. Signed by Judge Sherry R. Fallon on 7/25/2018. (lih) |
| Jul 25, 2018 | 64 | Order Setting Teleconference (4) Docket Text: ORDER Setting Teleconference: Plaintiffs' Counsel to initiate the call. A Telephone Conference is set for 8/17/2018 at 01:30 PM Eastern Time before Judge Mary Pat Thynge to discuss ADR. Signed by Judge Mary Pat Thynge on 7/25/2018. (fms) |
| Jul 24, 2018 | 63 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Vigen Salmastlian of Fenwick & West LLP - filed by Novo Nordisk A/S, Novo Nordisk Inc.. Motions referred to Sherry R. Fallon.(Noreika, Maryellen) |
| Jul 20, 2018 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Chief Magistrate Judge Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at http://www.ded.uscourts.gov/general-orders/magistrate-judges-standing-order-adr-mediation (fms) |
| Jul 11, 2018 | 62 | Notice (Other) (3) Docket Text: NOTICE of Change of Firm Affiliation by Novo Nordisk A/S, Novo Nordisk Inc. (Noreika, Maryellen) |
| Jul 2, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER REFERRING CASE to Magistrate Judge Mary Pat Thynge for Mediation. Ordered by Judge Sherry R. Fallon on 7/2/2018. (lih) |
| Jun 26, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [60] Stipulation filed by Novo Nordisk A/S, Novo Nordisk Inc.. Signed by Judge Sherry R. Fallon on 6/26/2018. (Polito, Rebecca) |
| Jun 26, 2018 | 61 | Report and Recommendations (17) Docket Text: REPORT AND RECOMMENDATIONS re: Claim Construction. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 7/10/2018. Signed by Judge Mary Pat Thynge on 6/26/2018. (fms) |
| Jun 22, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [60] Stipulation filed by Novo Nordisk A/S, Novo Nordisk Inc.. Signed by Judge Sherry R. Fallon on 6/22/2018. (Polito, Rebecca) |
| Jun 21, 2018 | 60 | Stipulation (2) Docket Text: STIPULATION to Further Amend the Scheduling Order and with Respect to Samples and Admissibility of Certain Records by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Jun 18, 2018 | 58 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant's First Amended Non-Infringement Contentions (2) Defendant's Second Amended Invalidity Contentions (3) Teva's Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-6) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jun 18, 2018 | 59 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Amended Infringement Contentions and Disclosures Under Paragraph 4(c) of the District of Delaware Default Standard and (2) Novo Nordisk's First Amended Validity and Secondary Considerations of Nonobviousness Contentions filed by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| May 30, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [57] STIPULATION TO EXTEND TIME for opening expert reports and rebuttal expert reports to July 13, 2018 and August 24, 2018, respectively. Signed by Judge Sherry R. Fallon on 5/30/2018. (lih) |
| May 25, 2018 | 57 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for opening expert reports and rebuttal expert reports to July 13, 2018 and August 24, 2018, respectively - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| May 17, 2018 | N/A | Markman Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Mary Pat Thynge - Markman Hearing held on 5/17/2018. ATTENDEES: PLTFF. - J. Oelke, Esq.; M. Norieka, Esq.; DEFT. - T. Fleming, Esq.; N. Hoeshen, Esq.; CLERK - Kincaid.( Court Reporter - Val Gunning ). (kjk) |
| May 16, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER- re [17] Scheduling Order. IT IS HEREBY ORDERED that: the pretrial conference previously set in this matter for 12/14/2018 at 09:00 AM before Magistrate Judge Thynge shall now take place before Magistrate Judge Fallon in Courtroom 6C. Ordered by Judge Sherry R. Fallon on 5/16/2018. (lih) |
| May 9, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [56] STIPULATION TO EXTEND TIME for supplementations under Rule 26(e) and for the completion of fact witness depositions to June 15, 2018. Signed by Judge Sherry R. Fallon on 5/9/2018. (lih) |
| May 8, 2018 | 56 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for supplementations under Rule 26(e) and for the completion of fact witness depositions to June 15, 2018 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| May 7, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER- granting [55] Letter Request. The status teleconference set for today at noon is CANCELLED. Ordered by Judge Sherry R. Fallon on 5/7/2018. (lih) |
| May 4, 2018 | 55 | Letter (1) Docket Text: Letter to The Honorable Sherry R. Fallon from Maryellen Noreika regarding postponement of May 7, 2018 status conference. (Noreika, Maryellen) |
| May 1, 2018 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The courtesy copy deficiency notice has been deleted due to being filed in error. (lih) |
| Apr 30, 2018 | 54 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Novo Nordisk and Novo Nordisk A/S's Notice of Deposition under Federal Rule of Civil Procedure 30(b)(6) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Apr 26, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED- re [53] MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, John Scheibeler, Ryan P. Johnson, Laura T. Moran, and So Yeon Choe. Signed by Judge Sherry R. Fallon on 4/26/2018. (lih) |
| Apr 26, 2018 | 53 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, John Scheibeler, Ryan P. Johnson, Laura T. Moran, and So Yeon Choe - filed by Novo Nordisk A/S, Novo Nordisk Inc.. Motions referred to Sherry R. Fallon.(Noreika, Maryellen) |
| Apr 25, 2018 | 52 | Claim Construction Opening Brief (74) Docket Text: CLAIM CONSTRUCTION OPENING BRIEF filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # (1) Exhibit A - L)(Noreika, Maryellen) Modified on 4/26/2018 (lih). |
| Apr 25, 2018 | 52 | Exhibit A - L (208) |
| Apr 24, 2018 | 51 | SO ORDERED (2) Docket Text: SO ORDERED re [50] Stipulation to Further Amend the Scheduling Order. The Joint Claim Construction Brief shall now be due on or before 4/25/18. Signed by Judge Mary Pat Thynge on 4/24/18. (cak) |
| Apr 23, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER- IT IS HEREBY ORDERED that: the court shall conduct a status telephone conference on 5/7/2018 at 12:00 PM before Judge Sherry R. Fallon. Counsel for the plaintiff shall initiate the call to 302-573-4557. Ordered by Judge Sherry R. Fallon on 4/23/2018. (lih) |
| Apr 23, 2018 | 50 | Stipulation (2) Docket Text: STIPULATION to Further Amend the Scheduling Order re [32] Stipulation by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Apr 19, 2018 | 49 | Status Report (4) Docket Text: Interim STATUS REPORT by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # (1) Exhibits A-B)(Noreika, Maryellen) |
| Apr 19, 2018 | 49 | Exhibits A-B (15) |
| Apr 17, 2018 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Docket clerk has deleted the stipulation previously filed as D.I. [49] due to document having the wrong case caption. Counsel is advised to refile the document with the correct case caption. (lih) |
| Apr 10, 2018 | 48 | Notice to Take Deposition (6) Docket Text: NOTICE to Take Deposition of Defendant Teva Pharmaceuticals USA, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) on May 1, 2018 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| Apr 2, 2018 | 46 | Order Setting Hearing on Motion (1) Docket Text: ORDER Setting Hearing on Claim Construction for 5/17/18 beginning at 9:00 AM Eastern Time in Courtroom 2B. Signed by Judge Mary Pat Thynge on 4/2/18. (cak) |
| Apr 2, 2018 | 47 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novo Nordisk's Reply Claim Construction Brief filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Mar 29, 2018 | 45 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Teva Pharmaceuticals USA, Inc.'s Notice of Deposition of Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Mar 15, 2018 | 44 | Order (1) Docket Text: ORDER: Consistent with the original scheduling order dated May 24, 2017 and the parties stipulation to amend the scheduling order dated January 5, 2018, IT IS ORDERED that the Markman hearing and the claim construction decision shall remain with Chief Magistrate Judge Thynge, who shall schedule a date and time for the Markman hearing. Should any objections to the Report and Recommendation on claim construction be filed, they shall be decided by the undersigned. Signed by Judge Joseph F. Bataillon on 3/15/18. (cak) |
| Mar 9, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER : Pursuant to the filing of this case, the Court issues the following order: This case shall be immediately referred to Magistrate Judge Sherry R. Fallon. Magistrate Judge Fallon shall issue a scheduling order when appropriate. Magistrate Judge Fallon shall handle all dispositive and nondispositive matters on all issues, including claim construction, except for summary judgments, Daubert motions and pretrial motions in limine. On all dispositive matters, the magistrate judge shall issue a report and recommendation. The parties have the right to file objections to the report and recommendation, or in the case of nondispositive matters, file an appeal of the magistrate judge's order, and the same shall be decided by the undersigned. The magistrate judge shall likewise handle all discovery matters, scheduling, and pretrial conferences. If the parties believe the magistrate judge has a conflict of interest with this case, the parties shall so notify the Court. IT IS SO ORDERED. Signed by Judge Joseph F. Bataillon on 3/9/18. (Brunswick, Amy) |
| Mar 6, 2018 | 42 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novo Nordisk's Initial Validity and Secondary Considerations of Non-Obviousness Contentions filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Mar 5, 2018 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Joseph F. Bataillon of the District of Nebraska (in lieu of Vacant Judgeship). Please include the initials of the Judge (JFB) after the case number on all documents filed. (rjb) |
| Mar 5, 2018 | N/A | Case Referred to Magistrate Judge (0) Docket Text: CASE REFERRED to Magistrate Judge Sherry R. Fallon. (rjb) |
| Mar 5, 2018 | 41 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant's First Amended Initial Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Feb 26, 2018 | 40 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Novo Nordisk's Opneing Claim Construction Brief filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jan 29, 2018 | 39 | Claim Construction Chart (11) Docket Text: CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # (1) Exhibit A-E)(Blumenfeld, Jack) |
| Jan 29, 2018 | 39 | Exhibit A-E (118) |
| Jan 26, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [38] STIPULATION TO EXTEND TIME to File Joint Claim Chart to January 29, 2018. Signed by Judge Mary Pat Thynge on 1/26/18. (cak) |
| Jan 26, 2018 | 38 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to File Joint Claim Chart to January 29, 2018 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Jan 24, 2018 | 36 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Teva Pharmaceuticals USA, Inc.'s Preliminary Proposed Constructions of Claim Terms to be Construed filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jan 24, 2018 | 37 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Proposed Claim Contructions filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jan 19, 2018 | 34 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Teva Pharmaceuticals USA, Inc.'s Preliminary Proposed Terms and Phrases for Construction filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jan 19, 2018 | 35 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Preliminary Claim Terms for Construction filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jan 5, 2018 | 32 | Stipulation (2) Docket Text: STIPULATION to Further Amend the Scheduling Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Jan 5, 2018 | 33 | SO ORDERED (2) Docket Text: SO ORDERED, re [32] Stipulation filed by Novo Nordisk A/S, Novo Nordisk Inc.. Signed by Judge Mary Pat Thynge on 1/5/18. (kjk) |
| Dec 21, 2017 | 31 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Defendant's Initial Invalidity Contentions and 2) Defendant's Initial Non-Infringement Contentions filed by Teva Pharmaceuticals USA, Inc..(Shaw, John) |
| Nov 13, 2017 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [30] Stipulation to Amend the Scheduling Order. Signed by Judge Mary Pat Thynge on 11/13/17. (cak) |
| Nov 10, 2017 | 30 | Stipulation (2) Docket Text: STIPULATION to Amend the Scheduling Order by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) |
| Oct 26, 2017 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [29] STIPULATION TO EXTEND TIME for the parties to amend or supplement the pleadings and to join additional parties to January 12, 2018 filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Mary Pat Thynge on 10/26/17. (cak) |
| Oct 26, 2017 | 29 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to amend or supplement the pleadings and to join additional parties to January 12, 2018 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Blumenfeld, Jack) |
| Oct 20, 2017 | 28 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Infringement Contentions and Disclosures Under Paragraph 4(c) of the District of Delaware Default Standard; (2) Responses and Objections of Novo Nordisk Inc. and Novo Nordisk A/S to Defendant's First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-68); and (3) Plaintiffs' Responses and Objections to Defendant's First Set of Interrogatory Requests to Plaintiffs (Nos. 1-6) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Oct 11, 2017 | 27 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Teva's Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-6) and 2) Defendant's Objections and Responses to Plaintiffs' First Set of Requests for Production (Nos. 1-78) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Sep 5, 2017 | 26 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Defendant's First Set of Requests to Plaintiffs for the Production of Documents and Things (Nos. 1-68); and 2) Defendant's First Set of Interrogatory Requests to Plaintiffs (Nos. 1-6) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Aug 22, 2017 | 25 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' First Set of Interrogatories (Nos. 1-6) and (2) Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-78) filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Aug 18, 2017 | 24 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Disclosures Under Paragraph 3 of the District of Delaware Default Standard and (2) Plaintiffs' Disclosures Under Paragraph 4(a) of the District of Delaware Default Standard filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jul 24, 2017 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [23] Stipulated Protective Order Pursuant to Federal Rule of Civil Procedures 26(c). Signed by Judge Mary Pat Thynge on 7/24/17. (cak) |
| Jul 20, 2017 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [22] STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order and to submit an ESI order to July 14, 2017. Signed by Judge Mary Pat Thynge on 7/20/17. (cak) |
| Jul 14, 2017 | 23 | Proposed Order (30) Docket Text: PROPOSED ORDER -- Protective Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Jul 7, 2017 | 22 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order and to submit an ESI order to July 14, 2017 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| Jun 30, 2017 | 20 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Rule 26(a) Initial Disclosure Statement filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jun 30, 2017 | 21 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure filed by Novo Nordisk A/S, Novo Nordisk Inc..(Noreika, Maryellen) |
| Jun 27, 2017 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [19] STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order and to submit an ESI order (if needed) to and including July 7, 2017. Signed by Judge Mary Pat Thynge on 6/27/17. (cak) |
| Jun 27, 2017 | 19 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order and to submit an ESI order (if needed) to and including July 7, 2017 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| May 30, 2017 | N/A | Oral Order (0) Docket Text: ORAL ORDER re [17] Scheduling Order: Although the Court has entered dates into the Scheduling Order [17] for the pretrial conference and trial, presently a District Court Judge is not assigned to this matter. If the parties jointly consent to have a Magistrate Judge conduct all proceedings in the case through trial, then Judge Thynge will preside over the pretrial conference and trial dates on the dates contained in D.I. 17. Otherwise, as the pretrial conference and trial dates approach, a District Judge will be assigned the case. Whether the pretrial and trial dates remain as in the Scheduling Order will depend on the availability of the District Judge. Ordered by Judge Mary Pat Thynge on 5/30/17. (cak) |
| May 24, 2017 | 17 | Scheduling Order (13) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 10/27/2017. Amended Pleadings due by 10/27/2017. Fact Discovery completed by 5/25/2018. Opening Expert Reports due by 6/29/2018. Rebuttal Expert Reports due by 8/10/2018. Expert Discovery due by 10/12/2018. A Status Conference ( via telephone ) is set for 3/30/2018 at 09:00 AM in Chambers before Judge Mary Pat Thynge. Status Report due by 3/23/2018. Tutorial on the technology due by 3/30/2018. Claim Construction Opening Brief due by 1/19/2018. Claim Construction Answering Brief due by 2/9/2018. Claim Construction Reply Brief due by 2/26/2018. Claim Construction Surreply Brief due by 3/15/2018. A Markman Hearing is set for 4/5/2018 at 9:30 AM. A Final Pretrial Conference is set for 12/14/2018 at 9:00 AM. A Bench Trial ( 8 Day ) is set for 1/15/2019 at 9:00 AM. Signed by Judge Mary Pat Thynge on 5/24/17. (kjk) Modified on 5/30/2017 (cak). |
| May 23, 2017 | 16 | Proposed Order (13) Docket Text: PROPOSED ORDER -- Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # (1) Letter to The Honorable Mary Pat Thynge enclosing order)(Blumenfeld, Jack) |
| May 23, 2017 | 16 | Letter to The Honorable Mary Pat Thynge enclosing order (1) |
| May 17, 2017 | 15 | Answer to Counterclaim (11) Docket Text: ANSWER to [9] Answer to Complaint, Counterclaim by Novo Nordisk A/S, Novo Nordisk Inc..(Blumenfeld, Jack) |
| May 15, 2017 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Mary Pat Thynge - Rule 16 Scheduling Conference held on 5/15/2017; Counsel shall file a Joint Final Scheduling Order by 5/23/2017; Attendees: Pltff - Blumenfeld, Oleke and Scheibler; Deft - Keller and Ben-Ami; Clerk - Kincaid (Court Reporter Stacey - Hawkins Reporting.) (kjk) Modified on 5/15/2017 (kjk). |
| May 10, 2017 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Robert Hyberg for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (crb) |
| May 10, 2017 | 14 | Proposed Order (14) Docket Text: PROPOSED ORDER -- Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Noreika, Maryellen) |
| May 3, 2017 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Gregory Springsted,Thomas F. Fleming,Leora Ben-Ami for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lmm) |
| May 3, 2017 | N/A | Order on Motion to Appear Pro Hac Vice (0) Docket Text: SO ORDERED granting [12] Motion to Appear Pro Hac Vice of Attorney Thomas F. Fleming, Leora Ben-Ami, Gregory Springsted, and Robert Hyberg - filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Mary Pat Thynge on 5/3/17. (cak) |
| May 2, 2017 | 12 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Thomas F. Fleming, Leora Ben-Ami, Gregory Springsted, and Robert Hyberg - filed by Teva Pharmaceuticals USA, Inc.. Motions referred to Mary Pat Thynge.(Keller, Karen) |
| Apr 26, 2017 | 9 | Answer to Complaint (26) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses, And, COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Apr 26, 2017 | 10 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals USA, Inc. filed by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) |
| Apr 26, 2017 | 11 | Order Setting Scheduling Conference (2) Docket Text: Order Setting Telephonic Scheduling Conference: A Rule 16 Scheduling teleconference is set for 5/15/2017 at 11:30 AM Eastern Time before Judge Mary Pat Thynge. Plaintiffs' counsel shall initiate the teleconference call. SEE ORDER FOR DETAILS. Signed by Judge Mary Pat Thynge on 4/26/17. (cak) |
| Mar 13, 2017 | N/A | Set/Reset Answer Deadline(s) (0) Docket Text: Set/Reset Answer Deadlines: Teva Pharmaceuticals USA, Inc. answer now due 4/26/2017. (cak) |
| Mar 13, 2017 | 7 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to Respond to the Complaint to April 26, 2017 - filed by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) |
| Mar 13, 2017 | 8 | Order (1) Docket Text: ORDER re [7] STIPULATION TO EXTEND TIME to Respond to the Complaint to April 26, 2017 filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Mary Pat Thynge on 3/13/17. (cak) |
| Mar 8, 2017 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Vacant Judgeship (2017). Please include initials of VAC after the case number on all documents filed. (rjb) |
| Mar 8, 2017 | N/A | Case Referred to Magistrate Judge (0) Docket Text: CASE REFERRED to Magistrate Judge Mary Pat Thynge. (This matter has been assigned to the Vacant Judgeship and referred to a Magistrate Judge for handling through case-dispositive motions. The Magistrate Judge has full authority permitted by law to manage this matter, including entering schedules through trial, deciding non-dispositive matters and making recommendations as to the resolution of dispositive matters. Litigants and counsel are reminded that they have the option of consenting to the Magistrate Judge to handle the case in full, including trial, or consenting to having a particular motion resolved by the Magistrate Judge.) (rjb) |
| Mar 6, 2017 | 1 | Main Document (9) |
| Mar 6, 2017 | 1 | Exhibit A-E (203) |
| Mar 6, 2017 | 2 | Civil Cover Sheet (2) |
| Mar 6, 2017 | 5 | Disclosure Statement (1) |
| Mar 6, 2017 | 1 | Main Document (9) |
| Mar 6, 2017 | 2 | Civil Cover Sheet (2) |
| Mar 6, 2017 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novo Nordisk Inc., Novo Nordisk A/S. Teva Pharmaceuticals USA, Inc. served on 3/6/2017, answer due 3/27/2017. (Noreika, Maryellen) |
| Mar 3, 2017 | 1 | Exhibit A-E (203) |
| Mar 3, 2017 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo A/S for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc. (ceg) |
| Mar 3, 2017 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceuticals USA, Inc. on 3/3/2017. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (ceg) |
| Mar 3, 2017 | 1 | Civil Cover Sheet (2) |
| Mar 3, 2017 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (ceg) |
| Mar 3, 2017 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/23/2017. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 7/23/2019. (ceg) |
| Mar 3, 2017 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,268,343 B1; 8,114,833 B2; 8,846,618 B2; 9,265,893 B2; RE41,956 E. (ceg) |
| Mar 3, 2017 | 1 | Complaint* (1) |
